Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences By: Simulations Plus, Inc. via Business Wire September 08, 2021 at 08:30 AM EDT Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at two upcoming investor conferences: BofA Securities 2021 Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021. The Company’s presentation will begin at 10:00 a.m. ET. The Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 22, 2021. The Company’s presentation will begin at 9:55 a.m. ET. Mr. O’Connor will host one-on-one meetings throughout the day at both events. Live webcasts of the Company’s presentations, along with the accompanying slide presentations, will be available on the Investors page of the Simulations Plus website; the webcast replays will be available for 90 days. For more information about the conferences or to schedule a one-on-one meeting with Simulations Plus, please contact Hayden IR at slp@haydenir.com. About Simulations Plus, Inc. Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries Cognigen, DILIsym Services, and Lixoft, we offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report. View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005446/en/Contacts Simulations Plus Investor Relations Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com Hayden IR Mr. Brian Siegel 346-396-8696 brian@haydenir.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences By: Simulations Plus, Inc. via Business Wire September 08, 2021 at 08:30 AM EDT Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at two upcoming investor conferences: BofA Securities 2021 Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021. The Company’s presentation will begin at 10:00 a.m. ET. The Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 22, 2021. The Company’s presentation will begin at 9:55 a.m. ET. Mr. O’Connor will host one-on-one meetings throughout the day at both events. Live webcasts of the Company’s presentations, along with the accompanying slide presentations, will be available on the Investors page of the Simulations Plus website; the webcast replays will be available for 90 days. For more information about the conferences or to schedule a one-on-one meeting with Simulations Plus, please contact Hayden IR at slp@haydenir.com. About Simulations Plus, Inc. Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries Cognigen, DILIsym Services, and Lixoft, we offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report. View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005446/en/Contacts Simulations Plus Investor Relations Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com Hayden IR Mr. Brian Siegel 346-396-8696 brian@haydenir.com
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O’Connor will be presenting at two upcoming investor conferences: BofA Securities 2021 Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021. The Company’s presentation will begin at 10:00 a.m. ET. The Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Wednesday, September 22, 2021. The Company’s presentation will begin at 9:55 a.m. ET. Mr. O’Connor will host one-on-one meetings throughout the day at both events. Live webcasts of the Company’s presentations, along with the accompanying slide presentations, will be available on the Investors page of the Simulations Plus website; the webcast replays will be available for 90 days. For more information about the conferences or to schedule a one-on-one meeting with Simulations Plus, please contact Hayden IR at slp@haydenir.com. About Simulations Plus, Inc. Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries Cognigen, DILIsym Services, and Lixoft, we offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on Twitter | Read our Environmental, Social, and Governance (ESG) Report. View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005446/en/
Simulations Plus Investor Relations Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com Hayden IR Mr. Brian Siegel 346-396-8696 brian@haydenir.com